QR kód

Postoperative adjuvant TACE combined with lenvatinib and immune checkpoint inhibitors for hepatocellular carcinoma with high recurrence risks: a multicenter retrospective study

Abstract Background and aims The role of adjuvant therapy for hepatocellular carcinoma (HCC) patients with high recurrence risks after curative resection remains controversial. This study aimed to assess the efficacy and safety of postoperative adjuvant transarterial chemoembolization (TACE) combine...

Celý popis

Uloženo v:
Hlavní autoři: Ziyue Huang, Taifeng Zhu, Xiaokun Chen, Mingjian Piao, Yang Tan, Chengjie Li, Kai Liu, Shanshan Wang, Lei Zhang, Shunda Du, Chengpei Zhu, Kang Zhou, Xiaobo Yang, Daobing Zeng, Haitao Zhao
Médium: Artigo
Jazyk:Inglês
Vydáno: BMC 2026-01-01
Edice:BMC Cancer
Témata:
Hepatocellular carcinoma
Adjuvant therapy
Transarterial chemoembolization
Lenvatinib
Immunotherapy
Recurrence-free survival
On-line přístup:https://doi.org/10.1186/s12885-026-15586-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky